

2ND

meeting of the European Research Consortium on ITP

NEW INSIGHTS INTO IMMUNE
THROMBOCYTOPENIA



Paris Crowne Plaza Paris République

April 23-24, 2026

Sylvain **Audia** - Dijon, France
 James B. **Bussel** - New York, USA
 Nichola **Cooper** - London, UK
 Etienne **Crickx** - Paris, France
 Waleed **Ghanima** - Oslo, Norway
 Bertrand **Godeau** - Paris, France
 Tomás José **González-López** - Burgos, Spain
 Alice **Hart** - London, UK
 Thomas **Kühne** - Basel, Switzerland
 Maria Luisa **Lozano** - Murcia, Spain
 Elisa **Lucchini** - Trieste, Italy
 Matthieu **Mahévas** - Paris, France
 Marc **Michel** - Paris, France
 Guillaume **Moulis** - Toulouse, France
 Andrew B. **Provan** - London, UK
 Francesco **Rodeghiero** - Vicenza, Italy
 Alexandra **Schifferli** - Basel, Switzerland
 John W. **Semple** - Lund, Sweden
 Karolin **Trautmann-Grill** - Dresden, Germany
 Francesco **Zaja** - Trieste, Italy

Thursday • April 23, 2026

01.30 pm REGISTRATION

01.45–02.00 pm WELCOME AND ERCI INTRODUCTION
 M.L. Lozano, M. Michel

02.00-03.30 pm **SESSION 1 NEW INSIGHTS IN THE BIOLOGY AND DIAGNOSIS OF ITP**
 Chairs: M. Michel, F. Zaja

- The role of platelets in innate and adaptive immunity – *J.W. Semple*
- Genetic predisposition for autoimmune cytopenias: lessons from Evans' syndrome – *E. Crickx*
- Predictive markers of treatment response: where do we stand? – *E. Lucchini*

03.30-04.00 pm Coffee break

04.00-05.30 pm **SESSION 2 GUIDELINES, DEFINITIONS AND REGISTRIES**
 Chairs: M.L. Lozano, G. Moulis

- Updating definitions and outcome criteria in ITP: an ERCI IWG initiative – *F. Rodeghiero*
- The new EHA guidelines: current status – *W. Ghanima*
- Why registries are useful: advances and gaps – *G. Moulis*

08.30–10.00 am **SESSION 3 ITP TREATMENT – ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES (PART 1)**

Chairs: T.J. González-López, T. Kühne

- Expanding the evidence on TPO-RAs in ITP through ERCI collaboration – *M.L. Lozano*
- Inhibiting Syk in ITP – *T.J. González-López*
- How BTK inhibitors may change the therapeutic approach in ITP – *N. Cooper*

10.00–10.30 am *Coffee break*

10.30 am–12.00 pm **SESSION 3 ITP TREATMENT – ADDRESSING UNMET CLINICAL NEEDS AND FUTURE THERAPIES (PART 2)**

Chairs: M. Michel, F. Rodeghiero

- Anti-CD38 monoclonal antibodies in ITP: current status – *W. Ghanima*
- Targeting BAFF/BAFF-R in ITP – *F. Zaja*
- Bispecific antibodies and CAR-T cells: do they have a place in ITP? – *K. Trautmann-Grill*
- Other novel therapeutic approaches (C1 inhibition, FcRn inhibition) – *S. Audia*

12.00–01.00 pm **SESSION 4 ITP IN SPECIFIC SITUATIONS**

Chairs: B. Godeau, F. Rodeghiero

- What's new in childhood/AYA ITP? – *T. Kühne, A. Schifferli*
- ITP during pregnancy: lessons from the last 5 years – *J.B. Bussel*
- Pharmacoeconomics of ITP: does cost matter? – *B. Godeau*

01.00–02.00 pm *Lunch*

02.00–03.30 pm **SESSION 5 QUALITY OF LIFE, ARTIFICIAL INTELLIGENCE, SECONDARY ITP**

Chairs: W. Ghanima, M. Lozano

- Quality of life in ITP – *A. Hart*
- What AI can bring to ITP – *D. Provan*
- Management of secondary ITP: what differs from primary ITP? – *M. Mahévas*

03.30–04.30 pm

SESSION 6 ABSTRACT PRESENTATIONS

Chairs: N. Cooper, D. Provan

- OC1.** EARLY T-CELL RECEPTOR REPERTOIRE FEATURES PREDICT LONG-TERM OUTCOME IN PAEDIATRIC IMMUNE THROMBOCYTOPAENIA – *A. Malik*
- OC2.** CIRCULATING CD8 T CELLS AS A POTENTIAL BIOMARKER OF NON-RESPONSE TO RITUXIMAB IN ITP – *R. Pralnaud*
- OC3.** DARATUMUMAB CAN LEAD TO LONG-LASTING REMISSIONS IN PATIENTS WITH REFRACTORY IMMUNE THROMBOCYTOPENIA BUT WITH A HIGH INCIDENCE OF SEVERE INFECTIONS – *E. Han*
- OC4.** GENERATION OF SYNTHETIC PATIENTS IN IMMUNE THROMBOCYTOPENIA: EXPERIENCE FROM THE ITALIAN GIMEMA ITP0918 REGISTRY – *G. Marsili*
- OC5.** THE PROLONG TRIAL: A TWO PHASE RANDOMIZED PLACEBO-CONTROLLED TRIAL TO OPTIMIZE RITUXIMAB RESPONSE WITH DEXAMETHASONE AND MAINTENANCE THERAPY WITH LOW DOSE RITUXIMAB IN IMMUNE THROMBOCYTOPENIA – *W. Ghanima*
- OC6.** BCMA-TARGETING T-CELL-ENGAGER THERAPY INDUCES SUSTAINED REMISSION IN IMMUNE THROMBOCYTOPENIA – *M.L. Hütter-Krönke*

04.30-04.45 pm

CONCLUSIONS AND ANNOUNCEMENT OF NEXT ERCI MEETING
M.L. Lozano, M. Michel

CONGRESS VENUE

Crowne Plaza Paris République

10 Pl. de la République - 75011 Paris (France)

REGISTRATION FEES

Registration Categories	Fee
Standard	€ 100,00
Exhibitor**	€ 60,00

The standard registration fee includes:

- Participation in the scientific sessions
- Conference kit
- Attendance certificate
- Lunches and coffee breaks

*** Exhibitor fee DOES NOT include conference kit and participation in the scientific sessions*

ABSTRACTS & POSTERS

Abstract e-book will be available on the meeting website. Selected abstracts as poster will be displayed on site in the poster area.

EBAH CME CREDITS

The program of the 2nd European Research Consortium on ITP Meeting has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 9 CME credits for Physicians, Biologists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is mandatory to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

OFFICIAL WEBSITE

www.erci2026.com

With the unrestricted educational grant of

PLATINUM



GOLD



SILVER



ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna

Phone +39 051 4210559

ercongressi@ercongressi.it

www.ercongressi.it

ER Congressi



SCIENTIFIC COMMITTEE

Meeting Chair: M. Michel

ERCI Co-Chairs: T. Kühne, M.L. Lozano

ERCI Board: N. Cooper, W. Ghanima, T.J. González-López, T. Kühne, M.L. Lozano, G. Moulis, D. Provan, F. Rodeghiero, F. Zaja

SCIENTIFIC SECRETARIAT ERCI

erci@ercigroup.org

www.ercigroup.org